196440

Batimastat

≥98% (HPLC), solid, Matrix metalloproteinase inhibitor, Calbiochem

• Synonyme(s) : Batimastat, (4-N-Hydroxyamino)-2 R-isobutyl-3 S-(thienylthiomethyl)succinyl)-L-phenylalanine-N-methylamide, BB-94, (4-N-Hydroxyamino)-2R-isobutyl-3S-(thienylthiomethyl)succinyl)-L-phenylalanine-N-methylamide, BB-94
• Formule empirique (notation de Hill): C₂₃H₃₁N₃O₄S₂
• Numéro CAS: 130370-60-4
• Poids moléculaire : 477.64
• Numéro MDL: MFCD00866533
• Code UNSPSC : 12352200
• Nomenclature NACRES : NA.77

Propriétés

• product name: Batimastat, Batimastat primarily used in Inhibition.
• Niveau de qualité: 100
• Pureté: ≥98% (HPLC)
• Forme: solid
• Fabricant/nom de marque: Calbiochem^®
• Conditions de stockage: OK to freeze; protect from light
• Couleur: off-white
• Solubilité: DMSO: 50 mg/mL
• Conditions d'expédition: ambient
• Température de stockage: 2-8°C
• InChI: 1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1
• Clé InChI: XFILPEOLDIKJHX-QYZOEREBSA-N

Description

Description générale

A Marimastat (Cat. No. 444289) type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases, including MMP-1, MMP-2, MMP-3/stromelysin, MMP-7/matrilysin, MMP-9, ΔMT1 (MMP-14 without TM domain), ADAM8, and ADAM17/TACE (IC₅₀ = 3, 4, 20, 6, 4, 2.08, 51.3, and 19 nM, respectively), by targeting both the substrate binding site and the active-site Zn²⁺, while being much less potent toward ACE (Angiotensin Converting Enzyme) or α-secretase (IC₅₀ = 1.6 and 3.3 µM, respectively). Batimastat is widely used in studying the involvement of MMPs in cancinogenesis and non-cancer pathological processes both in cultures in vitro and in animals in vivo. Also available as a 25 mM solution in DMSO (Cat. No. 508408).

A Marimastat (Cat. No. 444289) type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases, including MMP-1, MMP-2, MMP-3/stromelysin, MMP-7/matrilysin, MMP-9, ΔMT1 (MMP-14 without TM domain), ADAM8, and ADAM17/TACE (IC₅₀ = 3, 4, 20, 6, 4, 2.08, 51.3, and 19 nM, respectively), by targeting both the substrate binding site and the active-site Zn²⁺, while being much less potent toward ACE (Angiotensin Converting Enzyme) or α-secretase (IC₅₀ = 1.6 and 3.3 µM, respectively). Batimastat is widely used in studying the involvement of MMPs in cancinogenesis and non-cancer pathological processes both in cultures in vitro and in animals in vivo.

Conditionnement

Packaged under inert gas

Avertissement

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Autres remarques

Schlomann, U., et al. 2002. J. Biol. Chem.277, 48210.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Parvathy, S., et al. 1998. Biochemistry37, 1680.
Parvathy, S., et al. 1998. FEBS Lett.431, 63.
Yamamoto, M., et al. 1998. J. Med. Chem.41, 1209.
Moss, M.L., et al. 1997. Nature385, 733.
Eccles, S.A., et al. 1996. Cancer Res.56, 2815.
Brown, P.D. 1995. Advan. Enzyme Regul.35, 293.
Wang, X., et al. 1994. Cancer Res.54, 4726.
Davies, B., et al. 1993. Cancer Res.53, 2087.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable